OncLive TV

Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

January 9th 2015

Dr. Advani Compares Inotuzumab and Blinatumomab for ALL

January 8th 2015

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).

Dr. Sieber on the CHAARTED Trial

January 8th 2015

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma

January 7th 2015

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

Dr. Arteaga on PI3K Pathway Inhibitors

January 6th 2015

Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

Dr. Langer on Afatinib for Advanced Non-Small Cell Lung Cancer

January 5th 2015

Corey Langer, MD, the director of Thoracic Oncology at the University of Pennsylvania, discuses afatinib, which was approved in 2013 for first line EGFR-mutated advanced non-small cell lung cancer.

Dr. Morgan on the Future of Myeloma Treatment

January 2nd 2015

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.

Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

December 29th 2014

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Dr. Gomella on Labeling Low-Risk Prostate Cancer

December 26th 2014

Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.

Dr. Kumar on Ixazomib Combo for Multiple Myeloma Treatment

December 24th 2014

Shaji Kumar, MD, professor of medicine at the Mayo Clinic, discusses the use of the proteasome inhibitor ixazomib in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Dr. Ueno on Liquid Biopsy

December 22nd 2014

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.

Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

December 19th 2014

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Dr. Davids On Ipilimumab for Hematologic Malignancy Treatment

December 17th 2014

Dr. Carey Discusses Treatment Challenges in TNBC

December 4th 2014

Lisa A. Carey, MD, the Division Chief of Hematology and Oncology at the University of North Carolina and the Physician-in-Chief at North Carolina Cancer Hospital, discusses triple-negative breast cancer (TNBC) and the importance of understanding how it differs from other types of breast cancer.

Dr. Spigel Discusses the Development of Onartuzumab for the Treatment of Lung Cancer

December 2nd 2014

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, discusses the development of onartuzumab for the treatment of patients with lung cancer.

Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLL

November 26th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.

Dr. Wright Discusses the Molecular Biology of Ovarian Cancer

November 25th 2014

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the molecular biology of ovarian cancer.

Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL

November 24th 2014

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Dr. Oh Discusses Updates in Bladder Cancer Treatment

November 24th 2014

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses recent updates in bladder cancer treatment.